Medical Management of Fecal Incontinence

Gastroenterology

Volumn 126, Issue 1, 2004, Pages

  Scarlett, Yolanda ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALOSETRON; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIDIARRHEAL AGENT; ATROPINE; BISMUTH SALICYLATE; BULKING AGENT; CILANSETRON; CISAPRIDE; CODEINE; DIFENOXIN; DIPHENOXYLATE; ERYTHROMYCIN; GLYCEROL; KAOLIN PECTIN; LACTULOSE; LAXATIVE; LOPERAMIDE; MAGNESIUM CITRATE; MAGNESIUM HYDROXIDE; MAGNESIUM SULFATE; PHENYLEPHRINE; SEROTONIN 3 ANTAGONIST; SODIUM DIHYDROGEN PHOSPHATE; SORBITOL; SUGAR; TEGASEROD;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ANORECTAL PRESSURE; BLEEDING; CHRONIC DIARRHEA; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; DEFECATION; DEPRESSION; DIETARY FIBER; DISEASE COURSE; DIZZINESS; DROWSINESS; DRUG EFFECT; DRUG MECHANISM; DRUG OVERDOSE; ENDOSCOPY; FATIGUE; FECES ANALYSIS; FECES IMPACTION; FECES INCONTINENCE; FLATULENCE; FLUID INTAKE; HEMORRHOID; HUMAN; INTESTINE MOTILITY; ISCHEMIC COLITIS; MEDICAL CARE; MUSCLE CRAMP; NAUSEA; PARALYTIC ILEUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RASH; RECTUM MUCOSA; SIDE EFFECT; TOXIC MEGACOLON; URINE RETENTION; VISUAL IMPAIRMENT; VOMITING; XEROSTOMIA;

EID: 0346732091     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2003.10.007     Document Type: Conference Paper

References (47)

1. Nelson R, Norton N, Cautley E, Furner S. Community based prevalence of anal incontinence. JAMA 1995;274:559-561.
2. Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG, Whitehead WE, Janssens J, Funch-Jensen P, Corazziari E, Richter JE, Koch GG. US householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993;38:1569-1580.
3. Nelson R, Furner S, Jusadason V. Fecal incontinence in Wisconsin nursing homes: prevalence and associations. Dis Colon Rectum 1998;41:1226-1229.
4. Dey AN. Characteristics of elderly nursing residents: data from the 1995 National Nursing Home Survey. Adv Data 1997;289:1-8.
5. Burnett C, Whitehead WE, Drossman D. Psychological distress and impaired quality of life in patients with functional gastrointestinal disorders (abstr). Gastroenterology 1998;114:A729.
6. Rockwood TH, Church JM, Fleshman JW, Kane RL, Mavrantonis C, Thorson AG, Wexner SD, Bliss D, Lowry AC. Fecal Incontinence Quality of Life Scale: quality of life instrument for patients with fecal incontinence. Dis Colon Rectum 2000;43:9-17.
7. Chassagne P, Landrin I, Neveu C, Czernichow P, Bouaniche M, Doucet J, Denis P, Bercoff E. Fecal incontinence in the institutionalized elderly: incidence, risk factors, and prognosis. Am J Med 1999;106:185-190.
8. Levine MD. Children with encopresis: a descriptive analysis. Pediatrics 1975;56:412-416.
9. Whitehead WE, Wald A, Norton NJ. Treatment options for fecal incontinence. Dis Colon Rectum 2001;44:131-144.
10. Jafri S, Pasricha PJ. Agents used for diarrhea, constipation, and inflammatory bowel disease; agents used for biliary and pancreatic disease. In: Hardman JG, Limbird LE, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001:1037-1058.
11. Ruppin H. Loperamide - a potent antidiarrhoeal drug with actions along the alimentary tract. Aliment Pharmacol Ther 1987;1:179-190.
12. Musial F, Enck P, Kalveram KT, Erckenbrecht JF. The effect of loperamide on anorectal function in normal healthy men. J Clin Gastroenterol 1992;12:321-324.
13. Palmer KR, Corbett CL, Holdsworth CD. Double-blind cross-over study comparing loperamide codeine and diphenoxylate in the treatment of chronic diarrhea. Gastroenterology 1980;79:1272-1275.
14. Read MG, Read NW, Duthie HL. Effect of loperamide in anal sphincter function in patients with diarrhea (abstr). Gut 1979;20:A942.
15. Bergman L, Djarv L. A comparative study of loperamide and diphenoxylate in the treatment of chronic diarrhea caused by intestinal resection. Ann Clin Res 1981;13:402-405.
16. Johnson PC, Ericsson CD, DuPont HL, Morgan DR, Bitsura JA, Wood LV. Comparison of loperamide with bismuth subsalicylate for the treatment of acute traveller's diarrhea. JAMA 1986;255:757-760.
17. Karrar ZA, Abdulla MA, Moody JB, Macfarlane SB, Al Bwardy M, Hendrickse RG. Loperamide in acute diarrhea in childhood: results of a double-blind, placebo controlled clinical trial. Ann Trop Paediatr 1987;7:122-127.
18. Read M, Read NW, Barber DC, Duthie HL. Effects of loperamide on anal sphincter function in patients complaining of chronic diarrhea with fecal incontinence and urgency. Dig Dis Sci 1982;27:807-814.
19. Hallgren T, Fasth S, Delbro DS, Nordgren S, Oresland T, Hulten L. Loperamide improves anal sphincter function and continence after restorative proctocolectomy. Dig Dis Sci 1994;39:2612-2618.
20. Arnbjornsson E, Breland U, Kullendorff CM, Okmian L. Effect of loperamide on faecal control after rectoplasty for high imperforate anus. Acta Chir Scand 1986;152:215-216.
21. Portnoy BL, DuPont HL, Pruitt D, Abdo JA, Rodriguez JT. Antidiarrheal agents in the treatment of acute diarrhea in children. JAMA 1976;236:844-846.
22. Bliss DZ, Jung HJ, Savik K, Lowry A, LeMoine M, Jensen L, Werner C, Schaffer K. Supplementation with dietary fiber improves fecal incontinence. Nurs Res 2001;50:203-213.
23. DuPont HL, Flores Sanchez J, Ericsson CD, Mendiola Gomez J, DuPont MW, Cruz Luna A, Mathewson JJ. Comparative efficacy of loperamide hydrochloride and bismuth subsalicylate in the management of acute diarrhea. Am J Med 1990;88:15S-19S.
24. Hoffman BB, Taylor P. Neurotransmission: the autonomic and somatic motor nervous system. In: Hardman JG, Limbird LE, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001:146.
25. Carapeti EA, Kamm MA, Evans BK, Phillips RKS. Topical phenylephrine increases anal sphincter pressure. Br J Surg 1999;86:267-270.
26. Cheetham MJ, Kamm MA, Phillips RKS. Topical phenylephrine increases anal canal resting pressure in patients with faecal incontinence. Gut 2001;48:356-359.
27. Ritchie JA, Truelove SC. Comparison of various treatment for irritable bowel syndrome. BMJ 1980;281:1317-1319.
28. Farrar JT. The effects of drugs on intestinal motility. Clin Gastroenterol 1982;11:673-681.
29. Santoro GA, Eitan BZ, Pryde A, Bartolo MS. Open study of low-dose amitriptyline in the treatment of patients with idiopathic fecal incontinence. Dis Colon Rectum 2000;43:1676-1682.
30. Mayer EA, Berman S, Derbyshire SW, Suyenobu B, Chang L, Fitzgerald L. The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients. Aliment Pharmacol Ther 2002;16:1357-1366.
31. U.S. lets drug tied to deaths back on market. Available at: http://www.pharmacy forum.com/Lotronex. Accessed December 15, 2002.
32. Nygaard IE. Pharmacologic management of pelvic floor dysfunction. Obstet Gynecol Clin North Am 1998;25:867-882.
33. Jafri S, Pasricha PJ. Agents used for diarrhea, constipation, and inflammatory bowel disease; agents used for biliary and pancreatic disease. In: Hardman JG, Limbird LE, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001:1043.
34. van der Plas RN, Benninga MA, Buller HA, Bossuyt PM, Akkermans LM, Redekop WK, Taminiau JA. Biofeedback training in treatment of childhood constipation: a randomised controlled study. Lancet 1996;348:776-780.
35. Nolan T, Catto-Smith T, Coffey C, Wells J. Randomised controlled trial of biofeedback training in persistent encopresis with anismus. Arch Dis Child 1998;79:131-135.
36. Chassagne P, Jego A, Gloc P, Capet C, Trivalle C, Doucet J, Denis P, Bercoff E. Does treatment of constipation improve faecal incontinence in institutionalized elderly patients? Age Ageing 2000;29:159-164.
37. Voderholzer WA, Schatke W, Muhldorfer BE, Klauser AG, Birkner B, Muller-Lissner SA. Clinical response to dietary fiber treatment of chronic constipation. Am J Gastroenterol 1997;92:95-98.
38. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-related irritable bowel syndrome. Gastroenterology 2000;118:463-468.
39. Tougas G, Snape WJ Jr, Otten MH, Earnest DL, Langaker KE, Pruitt RE, Pecher E, Nault B, Rojavin MA. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2002;16:1701-1708.
40. Farup PG, Hovdenak N, Wetterhus S, Lange OJ, Ovde O, Tronstad R. The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation. Scand J Gastroenterol 1998;33:128-131.
41. Schutze K, Brandstatter G, Dragosics B, Judmaier G, Hentschel E. Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome. Aliment Pharmacol Ther 1997;11:387-394.
42. De Ponti F, Tonini M. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs 2001;61:317-332.
43. Rao SS, Welcher KD, Leistikow JS. Obstructive defecation: a failure of rectoanal coordination. Am J Gastroenterol 1998;93:1019-1020.
44. Hemorrhoids. Available at: http://ekhsin.morehead-st.edu/aha/ crs/hem.htm. Accessed December 18, 2002.
45. Hemorrhoid banding. Available at: http://ekhsin.morehead-st.edu/aha/crs/hemban.htm. Accessed December 18, 2002.
46. Dickey W, Garrett D. Hemorrhoid banding using videoendoscopic anoscopy and a single-handed ligator: an effective, inexpensive alternative to endoscopic band ligation. Am J Gastroenterol 2000;95:1714-1716.
47. Berkelhammer C, Moosvi SB. Retroflexed endoscopic band ligation of bleeding internal hemorrhoids. Gastrointest Endosc 2002;55:532-537.